Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma.
Weiwei JiaJianhui WuHongtao ZhangYan WuDaoning LiuZhen WangXiaopeng WangChengpeng LiChun-Yi HaoPublished in: Therapeutic advances in medical oncology (2024)
The combined treatment strategy involving eribulin, anlotinib, and camrelizumab showed promising efficacy and manageable safety in patients with advanced or metastatic RLPS, particularly in those with MLPS.